174 related articles for article (PubMed ID: 37611265)
1. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions.
Zubair AS; Rethana M; Ma A; McAlpine LS; Abulaban A; Munro BS; Patwa HS; Nowak RJ; Roy B
J Clin Neuromuscul Dis; 2023 Sep; 25(1):11-17. PubMed ID: 37611265
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis.
Morales-Ruiz V; Juárez-Vaquera VH; Rosetti-Sciutto M; Sánchez-Muñoz F; Adalid-Peralta L
Autoimmun Rev; 2022 Mar; 21(3):103019. PubMed ID: 34920107
[TBL] [Abstract][Full Text] [Related]
5. [Plasmapheresis in neurological diseases. Experience in 140 procedures in 47 patients].
Nogales-Gaete J; Valenzuela D; Liendo F; Vidal P; Gil G; Sáez D
Rev Med Chil; 2004 Mar; 132(3):295-8. PubMed ID: 15376565
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Intravenous Immunoglobulin in Neurological Diseases.
Lünemann JD; Quast I; Dalakas MC
Neurotherapeutics; 2016 Jan; 13(1):34-46. PubMed ID: 26400261
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
[TBL] [Abstract][Full Text] [Related]
8. Significant dermatological side effects of intravenous immunoglobulin.
Hurelbrink CB; Spies JM; Yiannikas C
J Clin Neurosci; 2013 Aug; 20(8):1114-6. PubMed ID: 23659929
[TBL] [Abstract][Full Text] [Related]
9. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
[TBL] [Abstract][Full Text] [Related]
10. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin use for neurologic diseases.
Koski CL; Patterson JV
J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
[TBL] [Abstract][Full Text] [Related]
12. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis.
Ortiz-Salas P; Velez-Van-Meerbeke A; Galvis-Gomez CA; Rodriguez Q JH
J Clin Neuromuscul Dis; 2016 Sep; 18(1):1-11. PubMed ID: 27552383
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
Chun W; Kim Y; Park SH; Choi SJ
J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
15. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
Soueidan SA; Dalakas MC
Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin Treatment in Neuromuscular Medicine.
Burakgazi AZ
J Clin Neuromuscul Dis; 2019 Jun; 20(4):182-193. PubMed ID: 31135621
[TBL] [Abstract][Full Text] [Related]
17. Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysis.
Ghimire A; Kunwar B; Aryal B; Gaire A; Bist A; Shah B; Mainali A; Ghimire B; Gajurel BP
J Clin Neurosci; 2024 Mar; 121():1-10. PubMed ID: 38306763
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of intravenous immunoglobulins in neurology.
Hughes RA; Dalakas MC; Cornblath DR; Latov N; Weksler ME; Relkin N
Clin Exp Immunol; 2009 Dec; 158 Suppl 1(Suppl 1):34-42. PubMed ID: 19883422
[TBL] [Abstract][Full Text] [Related]
19. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory therapies in neurologic critical care.
McDaneld LM; Fields JD; Bourdette DN; Bhardwaj A
Neurocrit Care; 2010 Feb; 12(1):132-43. PubMed ID: 19774497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
